List Trials for Recurrent Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

 

Chemotherapy for MDS Patients Prior Donor Stem Cell Transplant (2661)
Initial cytoreductive therapy for myelodysplastic syndrome prior to allogeneic hematopoietic cell transplantation (the ICT-HCT Study)

Investigator: Bart Scott, MD;   Conditions: Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD);    Status: Recruiting;   Study ID: NCT01812252

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride for Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) (2734)
A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD);    Status: Recruiting;   Study ID: NCT02044796

Depletion of T Cells From Allogeneic Stem Cell Grafts for the Prevention of GVHD (FHCRC-2222)
A Multi-center Phase II Study of Selective Depletion of CD45RA+ T cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

Investigator: Marie Bleakley, MD;   Conditions: Acute Lymphoid Leukemia (ALL);, Acute Myeloid Leukemia (AML), Hematologic Malignancies, Myelodysplastic Syndromes (MDS) Myeloproliferative Syndromes (MPD);    Status: Closed;   Study ID: NCT00914940

Decitabine Followed by Idarubicin and Cytarabine for AML or MDS
Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML

Investigator: Derek L. Stirewalt, MD;   Conditions: Leukemia, Myelodysplastic Syndromes;    Status: Recruiting;   Study ID: NCT01607645

Radioimmunotherapy + SCT for Advanced AML, ALL, or MDS
Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate

Investigator: John M. Pagel, MD;   Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT00988715

Adoptive Immunotherapy for Relapsed AML, MDS, or CML (FH 2498)
Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-specific T Cell Receptor for Patients With High Risk or Relapsed AML, MDS, or CML

Investigator: Dan Egan, MD;   Conditions: Acute Myeloid Leukemia (AML); Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Leukemia;    Status: Recruiting;   Study ID: NCT01640301

AMG 232 for Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Investigator: Pamela Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT02016729

GMI-1271 for Acute Myeloid Leukemia (20150436)
A Phase I/II, open-label multi-center study to determine safety, pharmacokinetics and efficacy of GMI-1271 in combination with chemotherapy in patients with acute myeloid leukemia

Investigator: Pamela Becker, MD, PhD;   Conditions: Leukemia, Acute Myeloid (AML);    Status: Recruiting;   Study ID: NCT02306291

Vadastuximab Talirine with Allogeneic Hematopoietic Stem Cell Transplant for Acute Myeloid Leukemia (9556)
A Phase 1/2 Study of Vadastuximab Talirine Administered in Sequence with Allogeneic Hematopoietic Stem Cell Transplant in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Investigator: Brenda Sandmaier, MD;   Conditions: Leukemia; Acute Myeloid (AML); Hematologic Malignancies;    Status: Recruiting;   Study ID: NCT02614560

AMG 330 Administered as Continuous Intravenous Infusion for Acute Myeloid Leukemia (9382)
A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects with Relapsed/Refractory Acute Myeloid Leukemia

Investigator: Roland Walter, MD;   Conditions: Leukemia, Acute Myeloid (AML); Hematologic Malignancies; Leukemia;    Status: Recruiting;   Study ID: NCT02520427